ABSTRACT
Many patients with painful diabetic neuropathy (PDN) do not achieve meaningful pain relief with standard of care. MEDI7352 is a unique bispecific fusion protein targeting two key mediators of pain, TNFα and NGF (at relatively low levels of suppression). We report a randomized, double-blind, placebo-controlled, Phase-2a study (NCT03755934/EudraCT-2018-002523-42) assessing efficacy and safety of MEDI7352 in patients aged ≥18 years with inadequately controlled PDN. Patients remained on background standard-of-care treatment and were randomized to placebo (n=54) or MEDI7352 intravenously (5μg/kg [n=6], 150μg/kg [n=16], 450μg/kg [n=36]). Primary endpoint was change in pain scores from baseline to Week 12 vs placebo on a numeric rating scale (NRS). Key secondary outcomes included change in pain scores from baseline at visits prior to Week 12 and responder rates. Of 112 patients randomized, 107 received ≥1 dose study medication; mean age (standard deviation [SD]) in the modified-intent-to-treat population was 60.5 (9.34) years; 62.6% males, 37.4% females. With MEDI7352 450μg/kg, change from baseline in pain scores at Week 12 vs placebo was: −1.39 [95% CI: −2.19 to −0.58], p=0.0009; at Week 12, mean (SD) pain scores decreased vs baseline by −2.70 (2.08); 66.7% of patients experienced decreased pain by ≥30% (p=0.0311 vs. placebo); 42.4% experienced decrease ≥50% (p=0.0029). MEDI7352 safety was similar to placebo; no adjudicated Rapidly Progressing Osteoarthritis (RPOA) type-1 or RPOA type-2 events were observed in any group. MEDI7352 achieved statistically significant and clinically meaningful pain reduction in patients with PDN vs placebo and provides an opportunity to change the paradigm for challenging-to-treat pain.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03755934/EudraCT-2018-002523-42
Funding Statement
This study was funded by AstraZeneca
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by all sites involved in the conduct of this study. Specifically: Bioethics Committee at the Kujawsko Pomorskie Regional Medical Chamber in Torun ul.Ignacego Danielewskiego 6, 87 to 100 Toru, Poland National Bioethics Committee for Medicines and Medical Devices Spitalul Colentina, Exterior Building C, 6, Dr.Grozovici Str., District 2, Bucharest, 021105, Romania South Central Oxford A Research Ethics Committee Bristol Research Ethics Committee Centre Whitefriars, Level 3 Block B, Lewins Mead, Bristol, BS1 2NT, United Kingdom The Health Research Ethics Committees Borgervaenget 3, stuen 2100 Kobenhavn 0, Denmark Belugyminiszterium, 1903 Budapest, Pf. 314, Hungary
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data which is not restricted by confidentiality considerations are available on reasonable request to the authors
